Abstract

CANCERPREVENTIONANDCONTROLRESEARCHPROGRAM PROGRAMCODE:CPC PROJECTSUMMARY/ABSTRACT ThemissionofCPCistopreventandcontrolcancerbyidentifyingfactorsthatcontributetocancer developmentandoutcomes,andconductinginterventionstoaddressthesefactors.
The SpecificAims ofour programareto:1)identifylifestyle,environmental,andgeneticriskfactorsintheetiologyofcancer;?2)assess thepatternsofcarereceivedbypatientswithcancertoidentifyeffectivestrategiestoimprovepatient outcomes,and3)conductandevaluatelifestylebehavioralinterventionsforcancerpreventionandcontrol. Dr.MelindaIrwinisAssociateDirectorforPopulationSciencesandco-leadstheCPCprogramalongwithDr. XiaomeiMa.Dr.Irwin?sexpertiseisinlifestylebehavioralinterventions,sosheoverseesresearchrelatedto Aim3.Dr.Ma?sexpertiseisinetiologyandoutcomes,sosheoverseesCPCresearchrelatedtoAims1and2. Together,Drs.IrwinandMafacilitatethecollaborationofCPCmemberswithmembersfromotherresearch programsanddisease-alignedresearchteams(DARTs)withthegoalofstimulatingtransdisciplinaryresearch thatwillimpactcancerriskandmortalityrateswithinandbeyondthestateofConnecticut. Currently,thereare38CPCmembers,withprimaryappointmentsin11departmentsandthreeschools.Our cancer-relatedfunding(directcostonly)hasincreased5%from$6.4Minthepreviouscycleto$6.7Minthe currentcycle,ofwhich$5.6M(84%)waspeerreviewedand$2.5MwasfromNCI.Ofthe793cancer-related publicationsbyCPCmembersfromJuly2012toJune2017(with30%and24%involvingintra-andinter- collaborations),manyhavehadamajorimpactonclinicaland/orpublichealthpractice.Drs.GrossandYu?s (RadiobiologyandRadiotherapy[RR]program)findingsofearlytoxicityfromprotonbeamtherapyforprostate cancerwascitedinthedecisionbyBlueShieldofCaliforniatostopreimbursingprotonbeamtherapyfor prostatecancer.Dr.Niccolai?sHPVvaccinationresearchhasimprovedvaccinationratesandhaslocal,state, andnationalimpact.Drs.Irwin,Sanft,Cartmel,andChagpar?swork,showingbenefitsofexerciseandweight lossoncancerbiomarkersandtreatment-relatedsideeffects,ischangingcancercaredeliverywith implementationoflifestyle/behaviorcounselingintheclinic. YCCandCPCleadershiphavedevelopedastrategicplantoguideourfutureinitiatives,withtheprimarygoal ofaddingdepthandbreadthtoourexistingstrengthsincanceroutcomesandlifestyle/behavioralresearch. Goalswithinthenextfiveyearsincluderecruitmentofadditionalfacultyincanceroutcomesanddissemination andimplementationresearch;?thesubmissionofaP01focusedonrandomizedtrialsofenergybalancein cancersurvivors;?twoT32applicationson1)obesityresearchand2)canceretiology,outcomesand survivorshipresearch;?andparticipatinginsubmissionofmoreSPOREapplicationswithCPCmembers leadingprojects.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016359-39S1
Application #
9772319
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
Project End
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
39
Fiscal Year
2018
Total Cost
Indirect Cost

  Institution

Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code

  Publications

Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564
Wang, Shi-Yi; Hsu, Sylvia H; Huang, Siwan et al. (2018) Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care. Health Serv Res 53:4291-4309
Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196
Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845
Altwerger, Gary; Bonazzoli, Elena; Bellone, Stefania et al. (2018) In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Mol Cancer Ther 17:1003-1011
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40

Showing the most recent 10 out of 675 publications